77 related articles for article (PubMed ID: 14716480)
1. [Regulation of hepatobiliary transporters in cholestatic liver disease].
Geier A; Gartung C; Matern S
Med Klin (Munich); 2004 Jan; 99(1):7-17. PubMed ID: 14716480
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia.
Chen HL; Liu YJ; Chen HL; Wu SH; Ni YH; Ho MC; Lai HS; Hsu WM; Hsu HY; Tseng HC; Jeng YM; Chang MH
Pediatr Res; 2008 Jun; 63(6):667-73. PubMed ID: 18327154
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis.
Geier A; Zollner G; Dietrich CG; Wagner M; Fickert P; Denk H; van Rooijen N; Matern S; Gartung C; Trauner M
Hepatology; 2005 Mar; 41(3):470-7. PubMed ID: 15723437
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver.
Geier A; Dietrich CG; Voigt S; Ananthanarayanan M; Lammert F; Schmitz A; Trauner M; Wasmuth HE; Boraschi D; Balasubramaniyan N; Suchy FJ; Matern S; Gartung C
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G831-41. PubMed ID: 15860642
[TBL] [Abstract][Full Text] [Related]
5. [Biliary function and its regulation].
Poupon R; Chignard N; Rosmorduc O; Barbu V; Housset C
Med Sci (Paris); 2004 Dec; 20(12):1096-9. PubMed ID: 15581462
[TBL] [Abstract][Full Text] [Related]
6. [Molecular mechanisms of bile formation and cholestatic diseases].
Poupon R
Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary transporters and drug-induced cholestasis.
Pauli-Magnus C; Meier PJ
Hepatology; 2006 Oct; 44(4):778-87. PubMed ID: 17006912
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients.
Nakai K; Tanaka H; Hanada K; Ogata H; Suzuki F; Kumada H; Miyajima A; Ishida S; Sunouchi M; Habano W; Kamikawa Y; Kubota K; Kita J; Ozawa S; Ohno Y
Drug Metab Dispos; 2008 Sep; 36(9):1786-93. PubMed ID: 18515332
[TBL] [Abstract][Full Text] [Related]
9. New molecular insights into the mechanisms of cholestasis.
Wagner M; Zollner G; Trauner M
J Hepatol; 2009 Sep; 51(3):565-80. PubMed ID: 19595470
[TBL] [Abstract][Full Text] [Related]
10. Genetic disorders and molecular mechanisms in cholestatic liver disease--a clinical approach.
Trauner M; Fickert P; Zollner G
Semin Gastrointest Dis; 2001 Apr; 12(2):66-88. PubMed ID: 11352122
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
Wagner M; Trauner M
Ann Hepatol; 2005; 4(2):77-99. PubMed ID: 16010241
[TBL] [Abstract][Full Text] [Related]
12. [Cholestasis and cholestatic liver diseases].
Poupon R
Gastroenterol Clin Biol; 2009; 33(8-9):778-88. PubMed ID: 19556086
[TBL] [Abstract][Full Text] [Related]
13. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice.
Teng S; Piquette-Miller M
J Pharmacol Exp Ther; 2005 Feb; 312(2):841-8. PubMed ID: 15456840
[TBL] [Abstract][Full Text] [Related]
14. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
15. [New molecular aspects of cholestatic liver diseases].
Trauner M; Fickert P; Stauber RE
Z Gastroenterol; 1999 Jul; 37(7):639-47. PubMed ID: 10458013
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects.
Roma MG; Crocenzi FA; Sánchez Pozzi EA
Clin Sci (Lond); 2008 May; 114(9):567-88. PubMed ID: 18377365
[TBL] [Abstract][Full Text] [Related]
17. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis.
Takeyama Y; Uehara Y; Inomata S; Morihara D; Nishizawa S; Ueda S; Matsumoto T; Tanaka T; Anan A; Nishimura H; Irie M; Iwata K; Shakado S; Sohda T; Sakisaka S
Liver Int; 2009 Mar; 29(3):406-14. PubMed ID: 18662272
[TBL] [Abstract][Full Text] [Related]
18. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
19. Analysis of bile acid-induced regulation of FXR target genes in human liver slices.
Jung D; Elferink MG; Stellaard F; Groothuis GM
Liver Int; 2007 Feb; 27(1):137-44. PubMed ID: 17241392
[TBL] [Abstract][Full Text] [Related]
20. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.
Geier A; Wagner M; Dietrich CG; Trauner M
Biochim Biophys Acta; 2007 Mar; 1773(3):283-308. PubMed ID: 17291602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
